Substitute Form PTO-1449 U

Sheet 1 of 6

U.S. Department of Commerce Patent and Trademark Office Attorney's Docket No. 06275-034001 Application No. 08/601,005

RECEIVED

Information Disclosure Statement by Applicant (Use several sheets if necessary) Applicant
Kjell Bäckström et al

DEC 2 7 2002

(37 CFR §1.98(b))

March 1, 1996

Group Art Unit 1619 (GILD TECH CENTER 1600/290

U.S. Patent Documents							
Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
×	AA	2,992,645	07/1961	Fowler			
	AB	3,671,625	06/1972	Altounyan			
	AC	4,462,983	07/1984	Azria			
	AD	4,524,769	06/1985	Wetterlin			
	AE	4,534,345	06/1985	Wetterlin			
	AF	4,537,772	08/1985	Alexander			
	AG	4,668,218	05/1987	Virtanen			
	AH	4,731,360	03/1988	Alexander			
	AI	4,907,583	03/1990	Wetterlin et al.			
	AJ	4,926,852	05/1990	Zoltan et al.			
	AK	5,122,127	06/1992	Stanley			
	AL	5,192,548	03/1993	Velasquez et al.			
	AM	5,254,330	10/1993	Ganderton et al.			
-	AN	5,260,306	11/1993	Boardman et al.			
	AO	5,288,498	02/1994	Stanley et al.			
	AP	5,320,094	06/1994	Laube et al.			
	AQ	5,341,800	08/1994	Clark et al.			
	AR	5,349,947	09/1994	Newhouse et al.			
	AS	5,352,461	10/1994	Feldstein et al.			
	AT	5,376,359	12/1994	Johnson			
	AU	5,376,386	12/1994	Ganderton et al.			
	AV	5,384,133	01/1995	Boyes et al.			
	AW	5,419,315	05/1995	Rubsamen			
	AX	5,437,271	08/1995	Hodson et al.			
	AY	5,451,569	09/1995	Wong et al.			
	AZ	5,458,135	10/1995	Patton et al.			
.27	AAA	5,474,759	12/1995	Fassberg et al.			

Examiner Signature

IIL In

Date Considered

30/ 2004

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Disclosure Form (PTO-1449)

Substitute orm PTO-1449 U.S. Department of Commerce (Modified orm PTO-1449 Patent and Trademark Office (Modified orm PTO-1449 Patent and Trademark Office (Modified orm PTO-1449 Patent and Trademark Office (Modified orm PTO-1449 (

			U.S. Pate	ent Documents			
Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
CVC	ABB	5,482,032	01/1996	Smith et al.			
	ACC	5,482,706	01/1996	Igari et al.		RF	CEIVE
	ADD	5,506,203 C1	02/2001	Bäckström et al.			1
	AEE	5,518,998 C1	02/2001	Bäckström et al			EC 27 2002
	AFF	5,658,878	08/1997	Bäckström et al		TECU	CENTER (100)
	AGG	5,707,644	01/1998	Illum		1EQH	OEITTE.
	AHH	5,747,445	05/1998	Bäckström et al	7		
	AII	5,830,853	11/1998	Bäckström et al			
	AJJ	5,858,968	01/1999	Weiner et al.			
	AKK	5,952,008	09/1999	Bäckström et al			
	ALL	5,997,848	12/1999	Patton et al.	T		
	AMM	6,051,256	04/2000	Platz et al.			
7	ANN	6,306,440	10/2001	Bäckström et al			
V	AOO						

	Foreign Patent Documents or Published Foreign Patent Applications							
Examiner	Desig.	Document	Publication	Country or			Trans	lation
Initial	ID	Number	Date	Patent Office	Class	Subclass	Yes	No
汉	APP	43 556/93	01/1994	Australia				
	AQQ	EP 0 023 359 A2	07/1980	European Patent Office				
	ARR	0 122 036	10/1984	European Patent Office				
	ASS	0 128 831	12/1984	European Patent Office				
	ATT	0 312 052 A1	10/1987	European Patent Office				
	AUU	0 364 235 A1	04/1988	European Patent Office				
	AVV	0 272 097	06/1988	European Patent Office				
	AWW	0 360 340 A1	03/1990	European Patent Office				
	AXX	0 455 463	11/1991	European Patent Office				
SC	AYY	0 383 751	09/1994	European Patent Office				

Examiner Signature Aullon	Date Considered 10/30/2004
EXAMINER: Initials citation considered. Draw line through citation if no next communication to applicant.	**
	Substitute Disclosure Form (PTO-1449)

Sheet 3 of 6

Substitute orm PTO-1449

U.S. Department of Commerce Patent and Trademark Office Information Disclosure Statement by Applicant (Use several sheets if necessary)

Kjell Bäckström et al.

Filing Date Group Ar

(37 CFR §1.98(b))

Filing Date Group Art Unit
March 1, 1996 1649 (666

	Foreign Patent Documents or Published Foreign Patent Applications							
Examiner	Desig.	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Tran: Yes	slation No
Initial	ID AZZ	Number JP 632 932	01/1988	Japan Japan	Ciass	Subclass	165	140
JY.								
	AAAA	JP 1 117 825	05/1989	Japan		REC	= 1	/ED
	ABBB	JP 4 041 421	02/1992	Japan		112	יווע	VEU
	ACCC	JP 4 149 126	05/1992	Japan		DE	G 27	2002
	ADDD	8 807 820	11/1986	Sweden				
	AEEE	1 242 211	08/1971	United Kingdom		TECH CE	NIEH 1	600,290
	AFFF	1 520 247	08/1978	United Kingdom				
	AGGG	1 569 611	06/1980	United Kingdom				
	АННН	WO 87/05213 A1	09/1987	WIPO				
	AIII	WO 90/04962	05/1990	WIPO				
	AJJJ	WO 91/16882	11/1991	WIPO				
	AKKK	WO 91/16929	11/1991	WIPO				
	ALLL	WO 91/18091 A1	11/1991	WIPO				
	AMMM	WO 92/04069	03/1992	WIPO				
	ANNN	WO 92/06704	04/1992	WIPO				
	A000	WO 93/25198	12/1993	WIPO				
	APPP	WO 94/22461	10/1994	WIPO				
	AQQQ	WO 95/00151	01/1995	WIPO				
	ARRR	WO 95/00128	01/1995	WIPO				
	ASSS	WO 96/19206	06/1996	WIPO -				
X	ATTT	WO 96/19207	06/1996	WIPO				
	AUUU							

	Other Documents (include Author, Title, Date, and Place of Publication)				
Г	Examiner	Desig.			
1	Initial	ID	Document		
T	又	AVVV	Almer et al. "Insulin Inhalation - At Last A Breakthrough," Diabetes Res. And Clin. Pract., 5:s163 (1988).		

Examiner Signature JK Om	Date Considered (0/30/2004
EXAMINER: Initials citation considered. Draw line through citation if no next communication to applicant.	it in conformance and not considered. Include copy of this form with



(37 CFR §1.98(b))

U.S. Department of Commerce Patent and Trademark Office

Attorney's Docket No. 06275-034001 Applicant

Filing Date

Application No. 08/601,005 RECEIVED

(Use several sheets if necessary)

DEC 2.7 2002 Group An Upit CH CENTER 1600/2900 Kjell Bäckström et al.

(37 CFR §	1.98(b))		Filing Date	Group Art Livin
_			March 1, 1996	Group Art Unit CH CENTE
-	Othe	Documents (include Au	thor, Title, Date, and Place	THE TOTAL
Examine Initial	r Des	9.	thor, Title, Date, and Place	of Publication)
I .				
130	AWV	W Aungst and Rogers, "Compari	son of the Effects of Veri	
101	+-	Buccal Insulin Delivery," Int.	Son of the Effects of Various Transm. J. Pharm. (Netherlands), 53/3, 227-2 of degradable storeh. "10 degradable storeh."	nucosal Absorption Promoters of
	AXX	X (1990) 197 102	of degradable starch "Internation	(1989).
	AYY	Brange et al "Mon-	J. Pharm. (Netherlands), 53/3, 227-3 of degradable starch" Internation	11 Journal of Pharmaceutics, 6.
	AII	Care, 13:923-954 (1990)	unns and Their Experimental and Cl	inical Implications " D:
L_ I	AZZ	Z Byron et al "Drug Delisses	a the Respiratory," Journal of Aer	Diabetes
	AAAA	Chien et al "Intra-	a the Respiratory," Journal of Aer	osol Medicine 7:40 75 (100 th
	AAAA			
	ABBB			one critical Reviews in
-		Industrial Pharmacy, 15(10), 16	ments in Systemic Delivery of Insult 501-1634 (1989).	in," Drug Development and
	ACCC	Colthorpe et al., "The Pharmaco	kinetics of Pulmon D.	
	-	Intratracheal," Pharmaceutica	501-1634 (1989). Skinetics of Pulmonary-Delivered Install Research, Vol. 9, No. 6, pp. 764-7 Fracer Aerosols in the Poble D.	ulin: A Comparison of
	ADDDI	Science Vol 18 N.	racer Aerosols in the Rabbit Pernis	09 (1992).
	AEEEE	Dahlbäck et al "Regional Ad	736 (1987). nistration of Drugs to the Rabbit Res Medicine, 1:222-223 (1988).	nory Tract," Journal of Aerosoi
	ALCEE	Absorption," Journal of Aerosol . Dempster et al., Anabolic Actions	nistration of Drugs to the Rabbit Res	Diratory Tract For
- 1 1	AFFFF	Dempster et al., Anabolic Actions	s of Parents. (1988).	Truck Effects on
1	1000-	709, (1993).	Medicine, 1:222-223 (1988). s of Parathyroid Hormone on Bone,	Endocrine Reviews 14: 690-
	AGGGG	Diabetes Mellitus" Ch VI in c.	1 10	
1 1	ATTTTTT	The Diabetes Control and Complia	ientific American Medicine, Scientific cations Trial Research Group, "The Complications in Insulin-Dependen	ic American, Inc., Apr. 1993
1 1	АНННН	of Diabetes on the Development.	. Complications in Inc. 1	Effect of Intensive Treatment
	AIIII	England Journal of Medicine, 329	cations Trial Research Group, "The Complications in Insulin-Dependent 977-986 (1993).	nt Diabetes Mellitus," New
		Parenteral abcomein-		
	AJJJJ	Eppstein and Longenecker, "Alterr	native Delivery Co. A. Paediatr. J., 2	23:293-297 (1987).
	VIVI	CRC Critical Reviews in Thorono.	Systems for Peptides	and Proteins A - D
+ 1"		Com Ct al., Palmitovicamitine		(1700).
1 1	ALLLL	Hoover et al., "Peptides are Better	ac Drug Carrier Systems, 5:99-139 aurface-active metabolite," FEBS Let Absorbed from the Lung than the Gullon, 8, pp. 1103-1106 (1902)	t., Vol. 390, pp. 1-5 (1996).
+-+				
Al				
1	NNNN	acreedy Wale Volunteers," Diabe	No. 8, pp. 1103-1106 (1992). macodynamics and Activity of Intrar etes, Vol. 42, pp. 1649-1655 (1993).	asally Administered Insulin
1	I Promise	roceedings of an interior size dis	tribution from different modification	0.5
AC	0000	ones, "Pulmonary absorption of in-	stribution from different modification schop on a new inhaler, May 21-22, ulin", (1998) Ph.D. Thesis, Welsh S.	1987 (London) pp. 00 00
A		Ollici, Dieler, "Aerocole for C		
AC	QQQQ K	öhler et al., "Nicht radioaktives V	nic Treatment," Lung, Supplement: 6 rfahren zur Messung der Lungenperr ng 13, Nr. Jun. 1987; 230-232.	77-684 (1990).
100				
AR AR	RRR La	sker, "The Diabetes Control and Co	ng 13, Nr. Jun. 1987; 230-232. Omplications Trial," The New Engla	Timalation von
-	32	9:1035-1036 (1993).	The New Engla	nd Journal of Medicine
niner Signature		7 /		

Examiner Signature Date Considered 10130/2004 EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	IJ
-	Ш
,	0
•	Ш
ء عــــــــــــــــــــــــــــــــــــ	<
3	П

Sheet & Application No. om PTO-1449 U.S. Department of Commerce Patent and Trademark Office Attorney's Docket No. 08/601,005 06275-034001 Applicant Information Disclosure Statement Kjell Bäckström et al by Applicant (Use several sheets if necessary) Group Art Unit Filing Date March 1, 1996 1619/6/6 (37 CFR §1.98(b))

	Other Documents (include Author, Title, Date, and Place of Publication)					
Examiner	Desig.	Document				
7	ASSSS	Laube et al., "Preliminary Study of the Efficacy of Insulin Aerosol Delivery by Oral Inhalation in Diabetic Patients," Journal of the American Medical Association, 239:2106-2109 (1993).				
	ATTTT	Lecluyse et al., "In Vitro Effects of Long-Chain Acylearnitines on the Permeability, Transepithelial Electrical Resistance and Morphology of Rat Colonic Mucosa," <i>J. Pharmacol. Exp. Ther.</i> , Vol. 265(2), pp. 355-62 (1933).				
	AUUUU	Lee et al., "Development of an aerosol dosage form containing insulin," Journal of Pharmaceutical Sciences, Vol. 65, No. 4, pp. 567-574 (1976).				
	AVVVV	Li, Yuping et al., "Effect of a Conjugated Bile Salt on the Pulmonary Absorption of Insulin in Rats," Eur. J. Pharm. Biopharm., Vol. 39, pp. 216-221 (1993).				
	AWWWW					
,	AXXXX	Longenecker et al., "Effects of Sodium Taurodihydrofusidate on Nasal Absorption of Insulin in Sheep," J. Pharm. Sci., 76(5): 351-355 (1987).				
	AYYYY					
	AZZZZ	Nagai et al., "Powder Dosage Form of Insulin for Nasal Administration," J. Controlled Release, 1:15-22 (1984).				
	AAAAA					
	ABBBBB	Aspects, (1984) Butterworth & Co., United Kingdom.				
	ACCCCC	O'Hagan and Illum, "Absorption of Peptides and Proteins from the Respiratory Tract and the Potential for Development of Locally Administered Vaccine," Critical Reviews in Therapeutic Drug Carrier 5ys, 753-597 (1990).				
	ADDDDI	Okumura et al., "Intratracheal delivery of insulin absorption from solution and aerosol by rat lung," International Journal of Pharmaceutics, Vol. 88, pp. 63-73 (1992).				
	AEEEEE	Pharmaceutical Applications, Lee et al, American Chemical Society, 301-309 (1987).				
	AFFFFF	Patton et al., "Bioavailability of Pulmonary Delivered Peptides and Proteins: α-interferon, Calcitonins and Parathyroid Hormones," Journal of Controlled Release, 28: 79-85 (1994).				
	AGGGGG	1/9-190(1992).				
	АНННН	Reeve et al., Anabolic Effect of Human Parathyroid Hormone Fragment on Trabecular Bone in Involutional Osteoporosis: A Multicentre Trial, British Medical Journal, pp. 1340-1344, (1980).				
	AIIIII	Remington's Pharmaceutical Science, 18th edition., p. 1079 (1990).				
	AJJJJJ	Ruin, "Diabetics May Not Need Their Insulin Shots," article in Sydsvenska (Dagbladet), Monday, Jun. 12, 1989.				
	AKKKK					
	ALLLLL	Salzman et al., "Intranasal Aerosolized Insulin Mixed-Meal Studies and Long-term Use in Type 1 Diabetes," The New England Journal of Medicine, 1312:1078-1084 (1985).				
X	АММММ	Schanker et al., "Species Comparison of Drug Absorption from the Lung Aerosol Inhalation or Intratracheal Injection," Drug Metabolism & Disposition, Vol. 14, pp. 79-88 (1986).				

		/1		
Examiner Signature	Shall	lo	Date Considered	30/20

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 6 of 6 Application No. U.S. Department of Commerce Attorney's Docket No. Form PTO-1449 08/601,005 Patent and Trademark Office 06275-034001 Applicant Information Disclosure Statement Kjell Bäckström et al by Applicant (Use several sheets if necessary) Filing Date Group Art Unit 1619 (6/1

(37 CFR §1.98(b))

	Other Documents (include Author, Title, Date, and Place of Publication)					
Examiner Initial	Desig.	Document				
TC ANNINI		Schluter et al., "Pulmonary Administration Type 1 Diabetics" Abstract #298, Diabetes, 33 (Supplement): 75A (1984).				
	A00000					
	APPPPP	PP Timsina et al., "Drug Delivery to the Respiratory Tract Using Dry Powder Inhalers," Int. J. Pharmaceutics, 101:1-13 (1994).				
	AQQQQQ					
	ARRRRR	Pharmaceutical Research, Vol. 5, pp. 500-506, (1986).				
	ASSSS	Wigley et al., "Insulin Across Respiratory Mucosae by Aerosol Delivery," Diabetes, 20:552-556 (1971).				
	ATITTT	Yamamoto et al., "Absorption Enhancement of Intrapulmonary Administered Insulin by Various Absorption," J. Pharm. Pharmacol., Vol. 46, pp. 14-18 (1994).				
	AUUUUL	Zingg et al., "Transhepatic Absorption and Biliary Excretion of Insulin," Can. J. Physiol. Pharmacol., 65:1982-1987 (1987).				
JC	AVVVV	RECEIV				

March 1, 1996

TECH CENTER : J0/2900

RECEIVED

DEC 2 7 2002

TECH CENTER 1600/2900

Examiner Signature	Date Considered
All to	1 180//20/ 1
EXAMINER: Initials citation considered.	Draw line through citation if not in conformance and not considered. Include copy of this form with
next communication to applicant.	0.100.150.150.150.100.144